A5037746646- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Grief, Bereavement, and Mental Health
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Patient Dignity and Privacy
- Pain Management and Opioid Use
- Nutrition and Health in Aging
- Neutropenia and Cancer Infections
- Pituitary Gland Disorders and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Myasthenia Gravis and Thymoma
- Patient-Provider Communication in Healthcare
Tohoku University
2016-2025
Tohoku University Hospital
2013-2023
Seirei Mikatabara General Hospital
2023
Dana-Farber Cancer Institute
2023
Dongguk University Ilsan Hospital
2022
Miyagi Prefectural Hospital Organization
2008-2021
Ijinkai Takeda General Hospital
2021
Hirosaki University
2021
Miyagi University
2021
Nagoya University
2013-2020
Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little known about how its efficacy and safety profile compares that standard chemotherapy.We randomly assigned 230 patients metastatic, non-small-cell who had not previously received chemotherapy receive gefitinib or carboplatin-paclitaxel. The primary end point was progression-free survival; secondary points...
Predictive models of EGFR-mutant tumor behavior point to alternative drug dosing strategies prevent and treat acquired resistance.
This study was undertaken to investigate the efficacy and feasibility of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.The EGFR gene status in various tumor samples obtained from NSCLC examined by DNA sequencing exons 18 23. Patients mutations received (250 mg/d) alone. The response rate, progression-free survival (PFS), toxicity profile were assessed prospectively.Between June 2004...
This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication chemotherapy as a result poor performance status (PS).Chemotherapy-naïve PS (patients 20 74 years age Eastern Cooperative Oncology Group 3 4, 75 79 2 >or= 80 1 4) who had EGFR examined by peptide nucleic acid-locked acid polymerase chain reaction...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) EGFR mutations; however, little known about efficacy and safety this combination compared that standard therapy EGFR- inhibitors alone.We randomly assigned 345 patients newly diagnosed metastatic NSCLC mutations to gefitinib carboplatin plus pemetrexed or alone. Progression-free survival (PFS), PFS2,...
This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) advanced/metastatic non-small-cell lung cancer (NSCLC) who had failed one or two chemotherapy regimens.The primary objective was to compare overall survival demonstrate noninferiority for relative docetaxel. An unadjusted Cox regression model used the analysis.Noninferiority not achieved (hazard ratio [HR], 1.12; 95.24% CI, 0.89 1.40) according predefined criterion (upper CI limit...
New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral irreversible ErbB family blocker, has preclinical activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models EGFR-activating mutations, including T790M.This was a Japanese single-arm phase II trial conducted stage IIIB to IV pulmonary adenocarcinoma progressed after ≥ 12 weeks of prior erlotinib and/or...
In non-small-cell lung cancer, an exon 19 deletion and L858R point mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-tyrosine kinase inhibitors. However, it is uncertain whether other uncommon EGFR mutations associated with sensitivity inhibitors.A post-hoc analysis assess prognostic factors was performed use patients (exon deletion, L858R, G719X, L861Q) who were treated gefitinib NEJ002 study, which compared carboplatin-paclitaxel as first-line...
Amrubicin, a new anthracycline agent, and topotecan are both active for previously treated small-cell lung cancer (SCLC). No comparative study of these agents has been reported. This randomized phase II was conducted to select amrubicin or future evaluation.Patients with SCLC platinum-containing chemotherapy were randomly assigned receive (40 mg/m(2) on days 1 through 3) (1.0 5). Patients stratified by Eastern Cooperative Oncology Group performance status (0, 1, 2) type relapse (chemotherapy...
Mutation in the epidermal growth factor receptor (EGFR) is frequently seen non-small cell lung cancers (NSCLCs), especially Asian females with adenocarcinoma. The frequency of mutation and factors associated requires to be elucidated by analyzing a large number consecutive clinical samples. We summarized result EGFR analysis for 1,176 patients performed at time diagnosis or relapse. PNA-LNA PCR clamp, highly sensitive detection method mutation, was employed. For fresh cases portion samples...
EML4-ALK is a lung cancer oncogene, and ALK inhibitors show marked therapeutic efficacy for tumors harboring this fusion gene. It remains unsettled, however, how the gene should be detected in specimens other than formalin-fixed, paraffin-embedded tissue. We here tested whether reverse transcription PCR (RT-PCR)-based detection of sensitive reliable approach.We developed multiplex RT-PCR system to capture transcripts applied technique our prospective, nationwide cohort non-small cell (NSCLC)...
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts with advanced NSCLC EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP. NEJ009, an open-label, randomized III study, was conducted to evaluate the superiority GCP vs G in progression-free survival (PFS), PFS2, and overall (OS). Methods: Pts newly diagnosed stage III/IV/ recurrent harboring activating mutations (exon 19 deletion or exon 21 L858R) were 1:1 250 mg PO QD (G 250mg...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved...
Abstract Background Cancer cachexia is a syndrome that does not fully recover with nutritional support and causes appetite loss body weight loss. It worsens patient's quality of life prognosis. In this study, the epidemiology in lung cancer, its risk factors impact on chemotherapy response rate prognosis were examined using national database Japan Lung Society. Understanding these things related to cancer important as starting point overcoming patients cancer. Methods 2012, 12 320 from 314...
Objectives: Anticipatory grief is associated with post-bereavement grief; however, reports on the influence of pre-loss depression are limited. Therefore, we investigated association between anticipatory family members and post-loss post-depression adjusted for depression. Methods: This cohort study included dying patients cancer. Questionnaires were distributed to them during hospitalization in four inpatient palliative care units from 2016 2017. We also administered follow-up...